Recent Evidences of the Use of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Management of Colorectal Cancer

Journal of Surgical Education

Volumn 64, Issue 2, 2007, Pages 114-119

  Dias, Andre Roncon ^a   Nahas, Sergio Carlos ^a   Camargo, Edwaldo Eduardo ^b   Nahas, Caio Sergio Rizkallah ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

chemoradiation; colon cancer; Medical Knowledge; positron emission tomography; rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; ARCITUMOMAB TC 99M; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE FREE SURVIVAL; ECHOGRAPHY; FALSE POSITIVE RESULT; HUMAN; INTERMETHOD COMPARISON; LAPAROTOMY; LIVER METASTASIS; LIVER RESECTION; LYMPH NODE METASTASIS; MEDICAL ASSESSMENT; METASTASIS POTENTIAL; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TREATMENT PLANNING; COLON TUMOR; METASTASIS; RECTUM TUMOR; SCINTISCANNING; TUMOR RECURRENCE;

COLONIC NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECTAL NEOPLASMS;

EID: 34047127370     PISSN: 19317204     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsurg.2006.11.004     Document Type: Review

References (38)

1. Rosenbaum S.J., Stergar H., Antoch G., Veit P., Bockisch A., and Kuhl H. Staging and follow-up of gastrointestinal tumors with PET/CT. Abdom Imaging 31 1 (2006) 25-35
2. Kumar R., Nadig M.R., and Chauhan A. Positron emission tomography: clinical applications in oncology. Part 1. Expert Rev Anticancer Ther 5 (2005) 1079-1094
3. Pauwels E.K., Ribeiro M.J., Stoot J.H., McCready V.R., Bourguignon M., and Maziere B. FDG accumulation and tumor biology. Nucl Med Biol 25 (1998) 317-322
4. Chung J.K., Lee Y.J., Kim C., et al. Mechanisms related to [18F]fluorodeoxyglucose uptake of human colon cancers transplanted in nude mice. J Nucl Med 40 (1999) 339-346
5. Young H., Baum R., Cremerius U., et al., European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 35 (1999) 1773-1782
6. Abdel-Nabi H., Doerr R.J., Lamonica D.M., et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 206 (1998) 755-760
7. Mukai M., Sadahiro S., Yasuda S., et al. Preoperative evaluation by whole-body 18Ffluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer. Oncol Rep 7 1 (2000) 85-87
8. Kantorova I., Lipska L., Belohlavek O., Visokai V., Trubac M., and Schneiderova M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 44 (2003) 1784-1788
9. Gearhart S.L., Frassica D., Rosen R., Choti M., Schulick R., and Wahl R. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 13 (2006) 397-404
10. Heriot A.G., Hicks R.J., Drummond E.G., et al. Does positron emission tomography change management in primary rectal cancer?. A prospective assessment. Dis Colon Rectum 47 (2004) 451-458
11. Cohade C., Osman M., Leal J., and Wahl R.L. Direct comparison of (18)F-FDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44 (2003) 1797-1803
12. Antoch G., Vogt F.M., Freudenberg L.S., et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 290 (2003) 3199-3206
13. Choi J.Y., Lee K.S., Kwon O.J., et al. Improved detection of second primary cancer using integrated [18F] fluorodeoxyglucose positron emission tomography and computed tomography for initial tumor staging. J Clin Oncol 23 (2005) 7654-7659
14. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
15. Fong Y., Saldinger P.F., Akhurst T., et al. Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 178 (1999) 282-287
16. Kalff V., Hicks R.J., Ware R.E., Hogg A., Binns D., and McKenzie A.F. The clinical impact of (18)F-FDG PET in patients with suspected or confirmed recurrence of colorectal cancer: a prospective study. J Nucl Med 43 (2002) 492-499
17. Wiering B., Krabbe P.F., Jager G.J., Oyen W.J., and Ruers T.J. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer 104 (2005) 2658-2670
18. Selzner M., Hany T.F., Wildbrett P., McCormack L., Kadry Z., and Clavien P.A. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg 240 (2004) 1027-1034 discussion 1035-1026
19. Khan S., Tan Y.M., John A., et al. An audit of fusion CT-PET in the management of colorectal liver metastases. Eur J Surg Oncol 32 (2006) 564-567
20. Lejeune C., Bismuth M.J., Conroy T., et al. Use of a decision analysis model to assess the cost-effectiveness of 18F-FDG PET in the management of metachronous liver metastases of colorectal cancer. J Nucl Med 46 (2005) 2020-2028
21. Zubeldia J.M., Bednarczyk E.M., Baker J.G., and Nabi H.A. The economic impact of 18FDG positron emission tomography in the surgical management of colorectal cancer with hepatic metastases. Cancer Biother Radiopharm 20 (2005) 450-456
22. Akhurst T., Kates T.J., Mazumdar M., et al. Recent chemotherapy reduces the sensitivity of [18F]fluorodeoxyglucose positron emission tomography in the detection of colorectal metastases. J Clin Oncol 23 (2005) 8713-8716
23. Flanagan F.L., Dehdashti F., Ogunbiyi O.A., Kodner I.J., and Siegel B.A. Utility of FDGPET for investigating unexplained plasma CEA elevation in patients with colorectal cancer. Ann Surg 227 (1998) 319-323
24. Lim J.W., Tang C.L., and Keng G.H. False positive F-18 fluorodeoxyglucose combined PET/CT scans from suture granuloma and chronic inflammation: report of two cases and review of literature. Ann Acad Med Singapore 34 (2005) 457-460
25. Ogunbiyi O.A., Flanagan F.L., Dehdashti F., et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 4 (1997) 613-620
26. Zervos E.E., Badgwell B.D., Burak Jr. W.E., Arnold M.W., and Martin E.W. Fluorodeoxyglucose positron emission tomography as an adjunct to carcinoembryonic antigen in the management of patients with presumed recurrent colorectal cancer and nondiagnostic radiologic workup. Surgery 130 (2001) 636-644
27. Moore H.G., Akhurst T., Larson S.M., Minsky B.D., Mazumdar M., and Guillem J.G. A case-controlled study of 18-fluorodeoxyglucose positron emission tomography in the detection of pelvic recurrence in previously irradiated rectal cancer patients. J Am Coll Surg 197 1 (2003) 22-28
28. Whiteford M.H., Whiteford H.M., Yee L.F., et al. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum. Dis Colon Rectum 43 (2000) 759-767 discussion 767-770
29. Simo M., Lomena F., Setoain J., et al. FDG-PET improves the management of patients with suspected recurrence of colorectal cancer. Nucl Med Commun 23 (2002) 975-982
30. Desai D.C., Zervos E.E., Arnold M.W., Burak Jr. W.E., Mantil J., and Martin Jr. E.W. Positron emission tomography affects surgical management in recurrent colorectal cancer patients. Ann Surg Oncol 10 1 (2003) 59-64
31. Libutti S.K., Alexander Jr. H.R., Choyke P., et al. A prospective study of 2-[18F] fluoro-2-deoxy-D-glucose/positron emission tomography scan, 99mTc-labeled arcitumomab (CEA-scan), and blind second-look laparotomy for detecting colon cancer recurrence in patients with increasing carcinoembryonic antigen levels. Ann Surg Oncol 8 (2001) 779-786
32. Even-Sapir E., Parag Y., Lerman H., et al. Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology 232 (2004) 815-822
33. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 (2004) 1731-1740
34. Guillem J.G., Puig-La Calle Jr. J., Akhurst T., et al. Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography. Dis Colon Rectum 43 1 (2000) 18-24
35. Amthauer H., Denecke T., Rau B., et al. Response prediction by FDG-PET after neoadjuvant radiochemotherapy and combined regional hyperthermia of rectal cancer: correlation with endorectal ultrasound and histopathology. Eur J Nucl Med Mol Imaging 31 (2004) 811-819
36. Chessin D.B., Arkhurst T., Yeung H., et al. Positron emission tomography during preoperative combined modality therapy for rectal cancer may predict ultimate pathologic response. A prospective analysis. [abstract]. J Clin Oncol 165 (2005) 3612
37. Guillem J.G., Moore H.G., Akhurst T., et al. Sequential preoperative fluorodeoxyglucose-positron emission tomography assessment of response to preoperative chemoradiation: a means for determining long term outcomes of rectal cancer. J Am Coll Surg 199 1 (2004) 1-7
38. Calvo F.A., Domper M., Matute R., et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 58 (2004) 528-535